|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
62,030,000 |
Market
Cap: |
903.16(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.48 - $21.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
11 |
Total Shares Sold |
261,204 |
293,400 |
293,400 |
298,772 |
Total Sell Value |
$4,645,136 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
Total People Sold |
5 |
5 |
5 |
5 |
Total Sell Transactions |
9 |
11 |
11 |
12 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-12-29 |
4 |
OE |
$1.51 |
$755 |
D/D |
500 |
44,968 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-11-30 |
4 |
AS |
$23.35 |
$11,675 |
D/D |
(500) |
44,468 |
|
30% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-11-30 |
4 |
OE |
$1.51 |
$755 |
D/D |
500 |
44,968 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-10-28 |
4 |
AS |
$20.69 |
$31,035 |
D/D |
(1,500) |
44,468 |
|
35% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-10-28 |
4 |
OE |
$1.51 |
$2,265 |
D/D |
1,500 |
45,968 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-09-28 |
4 |
AS |
$25.33 |
$12,665 |
D/D |
(500) |
44,468 |
|
-12% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-09-28 |
4 |
OE |
$1.51 |
$755 |
D/D |
500 |
44,968 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2020-09-18 |
4 |
AS |
$32.00 |
$586,848 |
D/D |
(18,339) |
83,807 |
|
-33% |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2020-09-17 |
4 |
AS |
$29.88 |
$1,330,019 |
D/D |
(44,512) |
102,146 |
|
-35% |
|
Galbraith Kenneth |
Director |
|
2020-09-09 |
4 |
S |
$27.11 |
$563,156 |
D/D |
(20,773) |
0 |
|
17% |
|
Galbraith Kenneth |
Director |
|
2020-09-09 |
4 |
OE |
$16.00 |
$361,103 |
D/D |
20,773 |
6,924 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-08-26 |
4 |
AS |
$27.10 |
$13,550 |
D/D |
(500) |
44,468 |
|
-23% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-08-26 |
4 |
OE |
$1.51 |
$755 |
D/D |
500 |
44,968 |
|
- |
|
Spitznagel Thomas |
Sr VP, BPD & Manufacturing |
|
2020-08-20 |
4 |
AS |
$26.87 |
$201,525 |
D/D |
(7,500) |
0 |
|
-18% |
|
Spitznagel Thomas |
Sr VP, BPD & Manufacturing |
|
2020-08-20 |
4 |
OE |
$7.51 |
$56,325 |
D/D |
7,500 |
7,500 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-07-27 |
4 |
AS |
$25.13 |
$114,319 |
D/D |
(4,489) |
44,468 |
|
-12% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-07-27 |
4 |
OE |
$0.94 |
$6,500 |
D/D |
4,489 |
48,468 |
|
- |
|
Peters Jeffrey Stuart |
General Counsel |
|
2020-07-02 |
4 |
AS |
$30.00 |
$6,060 |
D/D |
(202) |
0 |
|
-28% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-07-02 |
4 |
AS |
$30.00 |
$93,000 |
D/D |
(3,100) |
44,468 |
|
-28% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-07-02 |
4 |
OE |
$1.51 |
$4,681 |
D/D |
3,100 |
47,568 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-06-24 |
4 |
AS |
$28.49 |
$14,245 |
D/D |
(500) |
44,468 |
|
-25% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-06-24 |
4 |
OE |
$0.94 |
$470 |
D/D |
500 |
44,968 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-05-26 |
4 |
AS |
$26.59 |
$13,295 |
D/D |
(500) |
44,468 |
|
9% |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2020-05-26 |
4 |
OE |
$0.94 |
$470 |
D/D |
500 |
44,968 |
|
- |
|
Spitznagel Thomas |
Sr VP, BPD & Manufacturing |
|
2020-05-20 |
4 |
AS |
$25.30 |
$189,750 |
D/D |
(7,500) |
0 |
|
-0% |
|
286 Records found
|
|
Page 4 of 12 |
|
|